Brainstorm Cell Therapeutics, Inc. (BCLI)
0.98
-0.08
(-7.55%)
USD |
OTCM |
Aug 21, 16:00
Brainstorm Cell Therapeutics Shareholders Equity (Quarterly) : -11.60M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -11.60M |
| March 31, 2026 | -11.01M |
| December 31, 2025 | -9.985M |
| September 30, 2025 | -7.693M |
| June 30, 2025 | -6.057M |
| March 31, 2025 | -7.457M |
| December 31, 2024 | -7.764M |
| September 30, 2024 | -6.057M |
| June 30, 2024 | -3.527M |
| March 31, 2024 | -5.55M |
| December 31, 2023 | -4.858M |
| September 30, 2023 | -2.582M |
| June 30, 2023 | -3.882M |
| March 31, 2023 | -4.84M |
| December 31, 2022 | -3.015M |
| September 30, 2022 | 1.388M |
| June 30, 2022 | 7.851M |
| March 31, 2022 | 14.49M |
| December 31, 2021 | 19.34M |
| September 30, 2021 | 24.93M |
| June 30, 2021 | 30.17M |
| March 31, 2021 | 36.20M |
| December 31, 2020 | 35.46M |
| September 30, 2020 | 25.98M |
| June 30, 2020 | 9.822M |
| Date | Value |
|---|---|
| March 31, 2020 | 9.011M |
| December 31, 2019 | -12.22M |
| September 30, 2019 | -6.777M |
| June 30, 2019 | -4.516M |
| March 31, 2019 | 0.326M |
| December 31, 2018 | 5.016M |
| September 30, 2018 | 9.978M |
| June 30, 2018 | 12.87M |
| March 31, 2018 | 3.834M |
| December 31, 2017 | 5.88M |
| September 30, 2017 | 5.195M |
| June 30, 2017 | 7.29M |
| March 31, 2017 | 8.243M |
| December 31, 2016 | 9.902M |
| September 30, 2016 | 10.53M |
| June 30, 2016 | 11.87M |
| March 31, 2016 | 12.57M |
| December 31, 2015 | 14.13M |
| September 30, 2015 | 15.52M |
| June 30, 2015 | 17.84M |
| March 31, 2015 | 19.66M |
| December 31, 2014 | 6.675M |
| September 30, 2014 | 8.901M |
| June 30, 2014 | 10.60M |
| March 31, 2014 | 0.86M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| NovelStem International Corp. | -2.032M |
| Summit Therapeutics, Inc. | 629.98M |
| Kezar Life Sciences, Inc. | 65.24M |
| Protara Therapeutics, Inc. | 161.31M |
| Clene, Inc. | -24.78M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 0.788M |
| Total Liabilities (Quarterly) | 12.38M |
| Debt to Equity Ratio | -0.1185 |
| Current Ratio | 0.0255 |
| Net Debt Paydown Yield | 0.72% |